Early versus Late Use of Vedolizumab in Ulcerative Colitis
We explored the potential for differential efficacy of vedolizumab between "early" and "late" ulcerative colitis (UC) with evaluation of clinical, endoscopic, and histological endpoints.This was a multicentre, multinational open-label study in patients with moderately-to-severely...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2024
|
| Sorozat: | JOURNAL OF CROHNS & COLITIS
18 No. 4 |
| Tárgyszavak: | |
| doi: | 10.1093/ecco-jcc/jjad179 |
| mtmt: | 34316209 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/29497 |
| LEADER | 02755nab a2200397 i 4500 | ||
|---|---|---|---|
| 001 | publ29497 | ||
| 005 | 20241102060012.0 | ||
| 008 | 240206s2024 hu o 000 eng d | ||
| 022 | |a 1873-9946 | ||
| 024 | 7 | |a 10.1093/ecco-jcc/jjad179 |2 doi | |
| 024 | 7 | |a 34316209 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vermeire Séverine | |
| 245 | 1 | 0 | |a Early versus Late Use of Vedolizumab in Ulcerative Colitis |h [elektronikus dokumentum] / |c Vermeire Séverine |
| 260 | |c 2024 | ||
| 300 | |a 540-547 | ||
| 490 | 0 | |a JOURNAL OF CROHNS & COLITIS |v 18 No. 4 | |
| 520 | 3 | |a We explored the potential for differential efficacy of vedolizumab between "early" and "late" ulcerative colitis (UC) with evaluation of clinical, endoscopic, and histological endpoints.This was a multicentre, multinational open-label study in patients with moderately-to-severely active UC, defining "early" UC by a disease duration <4 years and bio-naïve and "late" UC by a disease duration >4 years and additional exposure to tumour necrosis factor antagonists. Patients received standard treatment with intravenous vedolizumab for 52 weeks (300 mg weeks 0-2-6, every 8 weeks thereafter without escalation). The primary endpoint was corticosteroid-free clinical remission with endoscopic improvement (total Mayo score ≤2 with no subscore >1) at both week 26 and 52.A total of 121 patients were included: in the "early" group 25/59 (42.4%) achieved the primary endpoint versus 19/62 (30.6%) in the "late" group (P = 0.18). There were no significant differences between the two groups in endoscopic improvement (week 26: "early" 32/59 [54.2%] vs. "late" 29/62 [46.8%]; P = 0.412; week 52: 27/59 [45.8%] vs. 25/62 [40.3%]; P = 0.546) or histological remission (Robarts Histopathology Index <3 without neutrophils in the epithelium and lamina propria) (week 26: 24/59 [40.7%] vs. 21/62 [33.9%]; P = 0.439; week 52: 22/59 [37.3%] vs. 22/62 [35.5%]; P = 0.837).No significant differences in clinical, endoscopic, and histological outcomes were observed between "early" and "late" disease. | |
| 650 | 4 | |a Gasztroenterológia és hepatológia | |
| 700 | 0 | 1 | |a Hanzel Jurij |e aut |
| 700 | 0 | 1 | |a Löwenberg Mark |e aut |
| 700 | 0 | 1 | |a Ferrante Marc |e aut |
| 700 | 0 | 1 | |a Bossuyt Peter |e aut |
| 700 | 0 | 1 | |a Hoentjen Frank |e aut |
| 700 | 0 | 1 | |a Franchimont Denis |e aut |
| 700 | 0 | 1 | |a Palatka Károly |e aut |
| 700 | 0 | 1 | |a Peeters Harald |e aut |
| 700 | 0 | 1 | |a Mookhoek Aart |e aut |
| 700 | 0 | 1 | |a Hertogh Gert de |e aut |
| 700 | 0 | 1 | |a Molnár Tamás |e aut |
| 700 | 0 | 1 | |a Moerkercke Wouter van |e aut |
| 700 | 0 | 1 | |a Lobatón Triana |e aut |
| 700 | 0 | 1 | |a Clasquin Esmé |e aut |
| 700 | 0 | 1 | |a et al. |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/29497/1/jjad179.pdf |z Dokumentum-elérés |